The initiation, development and evolution of metabolic and hormonal system, and cancers are regulated at multiple levels, such as epigenetic, genomic, transcriptional and post-transcriptional levels. These levels can be potential therapeutic targets for treatment. Clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease (CRISPR/Cas9) based programmable genome editing technology that provided multiple versatile and powerful tools has been used for precise gene modification and biomedical research. As such, CRISPR/Cas9 gene editing technology can be applied to many aspects of metabolic and hormonal system disease and cancer research. For example, the liver organ is amenable to somatic genome editing, and some delivery methods already allow for efficient editing in the whole liver. It is possible to develop CRISPR/Cas-based animal models for mimicking a broad range of metabolic disease and cancer in liver, such as in vivo whole-genome unbiased screening to dissect mechanisms of initiation and development of metabolic disease and liver cancer, to identify potential targets for drug development and gene/cell therapies. We can expect the application of CRISPR/Cas based gene editing tools will greatly expand the study of metabolic and hormonal system disease and cancer research, and provide new opportunities to develop novel therapeutic strategies and will offer great hopes in clinical treatments in future.
This Research Topic mainly focuses on the application of CRISPR/Cas9 tools (different types of CRISPR/Cas families or modified versions, i.e. nuclease, base editors, prime editors, or gene activators/repressors) on metabolic and hormonal system diseases and cancer research.
We welcome contributions in the form of Original Research Articles, Reviews, and Mini-Reviews that cover but are not limited to the following topics:
• Using CRISPR/Cas9 tools to build models (culture cell models or animal models) for metabolic and hormonal system disorders or cancers; i.e. Different delivery approaches of CRISPR/Cas9 tools for metabolic disorders or cancers study, i.e. mRNA-LNP (lipid nano-particle) delivery of CRISPR/Cas9 to liver for liver targeting sites;
• Development and evaluation of different CRISPR/Cas9 tools on metabolic and hormonal system disorders or cancers related targeting sites, i.e. evaluate the potential safety issues/concerns of CRISPR/Cas9 tools in vivo applications for metabolic disorders or cancers, i.e. Off-targeting issues, immune-response.
The initiation, development and evolution of metabolic and hormonal system, and cancers are regulated at multiple levels, such as epigenetic, genomic, transcriptional and post-transcriptional levels. These levels can be potential therapeutic targets for treatment. Clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease (CRISPR/Cas9) based programmable genome editing technology that provided multiple versatile and powerful tools has been used for precise gene modification and biomedical research. As such, CRISPR/Cas9 gene editing technology can be applied to many aspects of metabolic and hormonal system disease and cancer research. For example, the liver organ is amenable to somatic genome editing, and some delivery methods already allow for efficient editing in the whole liver. It is possible to develop CRISPR/Cas-based animal models for mimicking a broad range of metabolic disease and cancer in liver, such as in vivo whole-genome unbiased screening to dissect mechanisms of initiation and development of metabolic disease and liver cancer, to identify potential targets for drug development and gene/cell therapies. We can expect the application of CRISPR/Cas based gene editing tools will greatly expand the study of metabolic and hormonal system disease and cancer research, and provide new opportunities to develop novel therapeutic strategies and will offer great hopes in clinical treatments in future.
This Research Topic mainly focuses on the application of CRISPR/Cas9 tools (different types of CRISPR/Cas families or modified versions, i.e. nuclease, base editors, prime editors, or gene activators/repressors) on metabolic and hormonal system diseases and cancer research.
We welcome contributions in the form of Original Research Articles, Reviews, and Mini-Reviews that cover but are not limited to the following topics:
• Using CRISPR/Cas9 tools to build models (culture cell models or animal models) for metabolic and hormonal system disorders or cancers; i.e. Different delivery approaches of CRISPR/Cas9 tools for metabolic disorders or cancers study, i.e. mRNA-LNP (lipid nano-particle) delivery of CRISPR/Cas9 to liver for liver targeting sites;
• Development and evaluation of different CRISPR/Cas9 tools on metabolic and hormonal system disorders or cancers related targeting sites, i.e. evaluate the potential safety issues/concerns of CRISPR/Cas9 tools in vivo applications for metabolic disorders or cancers, i.e. Off-targeting issues, immune-response.